drugset / Trial / NCT06999980
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is for patients with stage 3 cutaneous melanoma and patients with mucosal melanoma who are able to have surgery to remove all tumour deposits. To improve the chance that melanoma will not recurr, new experimental combinations of a type of treatment called immunotherapy will be given before surgery.
Timeline
- Start
- 2026-02-09
- Primary completion
- 2028-03
- Completion
- 2038-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Comparator | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | — |